Risk Stratification and Treatment Intensification Strategies in mCSPC

In “Risk Stratification and Treatment Intensification Strategies in mCSPC,” our panel explores how clinicians use clinical, molecular, and genomic risk factors to personalize treatment decisions for patients with metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty discuss how disease volume, timing of metastasis, tumor burden, PSA kinetics, and patient comorbidities influence risk stratification and guide the selection of doublet, triplet, and metastasis-directed treatment approaches.

The panel reviews how synchronous versus metachronous disease presentation and high- versus low-volume metastatic burden shape treatment planning and determine which patients may be candidates for treatment intensification with chemotherapy or other combination strategies. Faculty emphasize the growing importance of tailoring treatment intensity to individual patient characteristics while balancing efficacy, toxicity, and quality-of-life considerations. The discussion highlights the expanding role of molecular profiling and next-generation sequencing (NGS) in treatment selection.

In addition, the expert faculty discuss the value of multidisciplinary collaboration among urologists, medical oncologists, radiation oncologists, pathologists, and genetics specialists when developing individualized treatment plans. They also explore emerging prognostic and predictive tools, including genomic classifiers and artificial intelligence-based models, that may further refine risk assessment and help optimize treatment selection as the mCSPC landscape continues to evolve.

Our next episode, “Emerging Treatment Strategies in mCSPC,” explores how PARP inhibitors, AKT inhibitors, metastasis-directed therapy, and PSMA-targeted approaches are reshaping treatment strategies in metastatic castration-sensitive prostate cancer. The panelists discuss how these emerging therapies may be integrated with established ADT plus ARPI regimens while balancing treatment intensification, de-intensification, and long-term disease management.